17 November 2023 - The MHRA has extended the licence of Vertex Pharmaceuticals’ cystic fibrosis drugs for children aged two to five years.

The treatments, Kaftrio (ivacaftor, tezacaftor and elexacaftor) and Kalydeco (ivacaftor), are already authorised for use in patients aged six years and older with at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

Read PM Live article